Institut Pasteur
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs by Stage
Trial / Program Status
Modality Mix
Indication Coverage
Program Types
Population Tags
Strong-Evidence Records
3 recordsOral R-azasetron besylate small molecule; Sensorion describes it as a 5-HT3 receptor antagonist and calcineurin inhibitor intended to protect and preserve inner-ear tissue from ototoxic and acute cochlear injury.
Dual-AAV intracochlear gene therapy delivers otoferlin to restore hearing in OTOF deficiency.
AAV-based gene therapy aims to restore connexin 26-related inner ear function in GJB2 hearing loss.
Checked Records With Caveats
6 checked · 0 open checksRecruiting French diagnostic study developing a non-invasive audiological and vestibular test battery, with neurocognitive questionnaires and genetic sampling, to characterize early-onset age-related hearing loss and guide precision fitting.
Recruiting study evaluating real-time AI-based speech-enhancement and denoising methods intended to improve speech-in-noise performance for auditory neuropathy spectrum disorders and broader hearing-aid use cases.
Recruiting prospective study evaluating 16 lip-reading/speechreading training sessions for adults with moderate-to-severe hearing loss who use hearing aids.